TNAX Biopharma Corporation is a biopharmaceutical company focused on the development and commercialization of novel antibody therapeutics that address unmet medical needs of patients with intractable diseases. Scientific co-founder, Akira Shibuya, M.D., Ph.D., professor at University of Tsukuba, is a renowned scientist who has discovered unique immunoreceptors and their ligands. He has revealed that these molecules play important roles in immunity and inflammation.(>Lab Link)
Immunoreceptors and their ligands are considered potential targets for new classes of therapeutics. TNAX Biopharma conducts joint research with University of Tsukuba and leverages intellectual property rights exclusively licensed from the university. Through drug discovery innovation and strategic alliances, TNAX continues to contribute to society by providing truly valuable therapeutic agents to patients around the world.
News
-
TNAX Biopharma Corporation and IMIDomics Inc. have entered into a license agreement
-
The University of Tsukuba and TNAX team discovered a target that ameliorates post-ischemic stroke neurological damages
-
University of Tsukuba and TNAX Biopharma Corporation identified an antibody and findings were published in Proc Natl Acad Sci USA
Leadership Team
Tak Mukohira, R.Ph., SM in MOT, CEO & Co-founder
Tak Mukohira has been CEO of TNAX Biopharma since its establishment in March 2018. He has extensive contacts in the biotech and pharmaceutical industries. Prior to launching TNAX, Tak was deeply involved in business development, corporate planning and venture capital operations at Mitsubishi Tanabe Pharma (MTP). Mr. Mukohira also served as President of MP Healthcare Venture Management Inc., the corporate venture capital arm of MTP, headquartered in Boston, and as a board member and observer for several biotech companies based in the US and Europe. He earned his SM in MOT from MIT Sloan School of Management and a BS in Pharmaceutical Sciences from Kyoto University.
Akira Shibuya, M.D.,Ph.D., Chief Scientific Officer & Co-founder
Akira Shibuya is Professor, University of Tsukuba and a world-famous immunologist. Dr. Shibuya had 12 years’ experience as a clinician before beginning his career in immunology research career as a post-doctoral fellow at DNAX Research Institute at Palo Alto, California. He has contributed many articles on immunoreceptors and their ligands to professional journals. Dr. Shibuya graduated from Hokkaido University Faculty of Medicine and earned an M.D. He holds a Ph.D. from University of Tsukuba.
Ichimaro Yamada, Ph.D., General Manager, R&D & Board Director
Ichimaro Yamada has 40-year broad and in-depth experience in drug research & development in Mitsubishi Tanabe Pharma Corporation and other biotech/pharma companies. He led a Japanese development team of telaprevir and won new drug approval. Dr. Yamada is a vice-president of Association for Promoting Drug Development (APDD). Ichimaro earned his Ph.D. from Kumamoto University.